oxidopamine has been researched along with Electron Transport Chain Deficiencies, Mitochondrial in 4 studies
Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The treatment of Parkinson's disease (PD) using stem cells has long been the focus of many researchers, but the ideal therapeutic strategy has not yet been developed." | 1.42 | Therapeutic potentials of human adipose-derived stem cells on the mouse model of Parkinson's disease. ( Chang, KA; Choi, HS; Kim, HJ; Oh, JH; Park, HG; Ra, JC; Suh, YH, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ay, M | 1 |
| Luo, J | 1 |
| Langley, M | 1 |
| Jin, H | 1 |
| Anantharam, V | 1 |
| Kanthasamy, A | 1 |
| Kanthasamy, AG | 1 |
| Lin, CY | 1 |
| Tsai, CW | 1 |
| Choi, HS | 1 |
| Kim, HJ | 1 |
| Oh, JH | 1 |
| Park, HG | 1 |
| Ra, JC | 1 |
| Chang, KA | 1 |
| Suh, YH | 1 |
| Stack, EC | 1 |
| Ferro, JL | 1 |
| Kim, J | 1 |
| Del Signore, SJ | 1 |
| Goodrich, S | 1 |
| Matson, S | 1 |
| Hunt, BB | 1 |
| Cormier, K | 1 |
| Smith, K | 1 |
| Matson, WR | 1 |
| Ryu, H | 1 |
| Ferrante, RJ | 1 |
4 other studies available for oxidopamine and Electron Transport Chain Deficiencies, Mitochondrial
| Article | Year |
|---|---|
Molecular mechanisms underlying protective effects of quercetin against mitochondrial dysfunction and progressive dopaminergic neurodegeneration in cell culture and MitoPark transgenic mouse models of Parkinson's Disease.
Topics: Adrenergic Agents; Animals; Antioxidants; Cell Line, Transformed; Cell Survival; DNA-Binding Protein | 2017 |
PINK1/parkin-mediated mitophagy pathway is related to neuroprotection by carnosic acid in SH-SY5Y cells.
Topics: Abietanes; Cell Line, Tumor; Cytochromes c; Humans; Membrane Potential, Mitochondrial; Mitochondria; | 2019 |
Therapeutic potentials of human adipose-derived stem cells on the mouse model of Parkinson's disease.
Topics: Adipocytes; Animals; Disease Models, Animal; Dopaminergic Neurons; Electron Transport Complex I; Hum | 2015 |
Therapeutic attenuation of mitochondrial dysfunction and oxidative stress in neurotoxin models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cystamine; Disease Models, Animal; Dru | 2008 |